Clinical Trial Update: Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of chidamide and fulvestrant for HR+/HER2- breast cancer after prior CDK4/6 inhibitor therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Advanced Breast Cancer

Drugs mentioned

• Chidamide (chidamide)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Fudan University | Conditions: Hormone Receptor-positive Advanced Breast Cancer | Phase 2 | Status: UNKNOWN